• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New Oracle Cloud Services Help Pharmas Accelerate Clinical Trial Site Feasibility Assessment and Patient Recruitment

    10/29/24 8:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology
    Get the next $ORCL alert in real time by email

    Developments are the latest in Oracle's commitment to bridge the gap between clinical research and patient care to help speed the development of and access to breakthrough treatments   

    NASHVILLE, Tenn., Oct. 29, 2024 /PRNewswire/ -- Oracle Health Summit -- To help life sciences organizations accelerate and reduce the cost and complexity of clinical trials so they can get lifesaving treatments to market faster, Oracle Life Sciences today announced Oracle Site Feasibility and Oracle Patient Recruitment Cloud Services. Running on Oracle Cloud Infrastructure (OCI), the new Oracle Life Sciences services benefit from best-in-class security and trust in handling and storing Protected Health Information in compliance with HIPAA regulations. In addition, OCI's high performance and availability mean these new solutions, coupled with Oracle's Real World Data assets and life science and clinical applications, help pharmaceutical companies, CROs and researchers to select clinical trial sites and recruit patients more quickly.

    (PRNewsfoto/Oracle)

    "Patient recruitment is the cornerstone of any clinical trial, but identifying the right sites and recruiting the right patients at scale is difficult, time-consuming, and costly," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "Our new site feasibility and patient recruitment cloud services are an example of how Oracle's extensive expertise in life sciences and healthcare are bridging the gap between clinical research and patient care. We can provide insights based on our secure, authorized, and vast Electronic Health Record data that helps sponsors and CROs to intelligently select clinical trial sites and enable site study teams to identify and enroll qualified patients more efficiently and effectively."

    According to Deloitte research1, patient recruitment accounts for 32% of clinical trial costs, making it the largest expense in the process. Additionally, $1.9 billion is spent on recruitment annually,2 even though 72% of trial participants are already patients at a site. Oracle Site Feasibility and Oracle Patient Recruitment can help life sciences organizations overcome these challenges and dramatically reduce the cost of running clinical trials.

    Through the existing Study Startup solution and Oracle's extensive deidentified Electronic Health Record (EHR) data from participating healthcare systems, Oracle Site Feasibility Cloud Service enables life sciences organizations to quickly and easily identify the most advantageous sites for their clinical trials. Within activated clinical trial sites, Oracle Patient Recruitment Cloud Service can increase enrollment efficiency by informing authorized study teams of identified patients within their health system who could potentially meet trial criteria based on their clinical profile.

    Activate sites faster and accelerate study timelines

    With Oracle Site Feasibility, life science organizations can accelerate the site-selection process and have more visibility into untapped sites. The new service enables life science organizations to more quickly find viable clinical trial site locations by surfacing trial-specific eligible and partially eligible patients from participating healthcare facilities. This solution uses Oracle's deidentified EHR clinical data to run feasibility queries across patient records, analyzing key data points, such as past site performance and qualified patients per site. This data granularity helps life science organizations to intelligently select sites with the highest volume of potential eligible patients.

    Recruit the right patients more quickly

    Oracle Patient Recruitment is available globally for life sciences customers to help activate sites faster and provide deeper patient insights to help study teams be more aware of any retention or dropout risks and recruit the right patients for the trial. It uses Health Data Intelligence (HDI) as its underlying technology infrastructure to surface data directly from the EHR and identify eligible and partially eligible patients for potential trial participation.

    Oracle Patient Recruitment calculates an eligibility score for qualified patients and provides important insights to the study team about why a patient qualifies for a trial or where they may fall short. This level of detail lets study teams quickly identify what next steps should be taken with the trial candidate and eliminates time wasted searching for additional context in the medical record. Oracle Patient Recruitment also incorporates health system registration and scheduling data, giving study teams visibility to upcoming and past appointment details. Using these additional insights, the study team can customize a visit schedule based on the patient's unique situation to help ensure the patient does not drop out – another step in putting the patient's care first. 

    For more information about Oracle Site Feasibility and Oracle Patient Recruitment Cloud Services, visit: https://www.oracle.com/life-sciences/

    To join segments of the Oracle Health Summit virtually, visit: https://www.oracle.com/health/health-summit/

    About Oracle Life Sciences

    Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements – empowering the life sciences industry to improve patient outcomes. Learn more at oracle.com/lifesciences

    About Oracle

    Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE:ORCL), please visit us at www.oracle.com.

    Trademarks

    Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

    1 Taylor K, Properzo, F, et al. Intelligent clinical trials. Deloitte Centre for Health Insights. 2020. https://www2.deloitte.com/content/dam/insights/us/articles/22934_intelligent-clinical-trials/DI_Intelligent-clinical-trials.pdf

    2
    Idnay B, Fang Y, Butler A, et al. Uncovering key clinical trial features influencing recruitment. J Clin Transl Sci. 2023 Sep 4;7(1):e199. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565197/

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/new-oracle-cloud-services-help-pharmas-accelerate-clinical-trial-site-feasibility-assessment-and-patient-recruitment-302289032.html

    SOURCE Oracle

    Get the next $ORCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What are the new services announced by Oracle Life Sciences?

      Oracle has launched new services named Oracle Site Feasibility and Oracle Patient Recruitment Cloud Services to aid life sciences organizations in accelerating clinical trials and reducing costs.

    • How does Oracle Site Feasibility Cloud Service assist organizations?

      The Oracle Site Feasibility Cloud Service helps organizations quickly identify the best sites for clinical trials, leveraging deidentified Electronic Health Record data.

    • What percentage of clinical trial costs is attributed to patient recruitment?

      Patient recruitment accounts for 32% of clinical trial costs, which is the largest single expense in the clinical trial process.

    • What is the primary goal of the Oracle's new clinical trial services?

      The new services aim to improve efficiency in selecting clinical trial sites and rapidly recruiting suitable patients to ensure timely access to treatments.

    • What technology does the Oracle Patient Recruitment Cloud Service utilize to identify qualified patients?

      Oracle Patient Recruitment uses Health Data Intelligence technology to analyze patient records and calculate eligibility scores for potential trial candidates.

    Recent Analyst Ratings for
    $ORCL

    DatePrice TargetRatingAnalyst
    3/24/2026$200.00Buy
    BofA Securities
    3/11/2026$210.00Neutral → Overweight
    Analyst
    3/11/2026$205.00 → $200.00Outperform
    BMO Capital Markets
    3/11/2026$185.00 → $210.00Outperform
    Oppenheimer
    2/25/2026$185.00Perform → Outperform
    Oppenheimer
    2/9/2026Buy → Hold
    Melius
    2/9/2026$180.00Neutral → Buy
    DA Davidson
    2/4/2026$270.00 → $205.00Outperform
    BMO Capital Markets
    More analyst ratings

    $ORCL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Oracle Corporation

    SCHEDULE 13G/A - ORACLE CORP (0001341439) (Subject)

    3/27/26 11:08:37 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-Q filed by Oracle Corporation

    10-Q - ORACLE CORP (0001341439) (Filer)

    3/11/26 6:38:49 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Oracle Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - ORACLE CORP (0001341439) (Filer)

    3/10/26 4:12:51 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $ORCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on Oracle with a new price target

    BofA Securities resumed coverage of Oracle with a rating of Buy and set a new price target of $200.00

    3/24/26 8:49:56 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Oracle upgraded by Analyst with a new price target

    Analyst upgraded Oracle from Neutral to Overweight and set a new price target of $210.00

    3/11/26 8:29:46 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    BMO Capital Markets reiterated coverage on Oracle with a new price target

    BMO Capital Markets reiterated coverage of Oracle with a rating of Outperform and set a new price target of $200.00 from $205.00 previously

    3/11/26 8:12:23 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $ORCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairhead Rona Alison bought $112,258 worth of shares (480 units at $233.87), increasing direct ownership by 2% to 22,110 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    7/9/25 4:39:51 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    3/21/25 8:43:30 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Director Moorman Charles W bought $947,913 worth of shares (5,500 units at $172.35) (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    2/14/25 4:41:16 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $ORCL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oracle Scales Up Nashville Offices to Support Rapid Growth

    New lease at the Neuhoff Development adds over 116,000 square feet to Oracle's Nashville footprintAUSTIN, Texas, March 26, 2026 /PRNewswire/ -- To accommodate future growth of its Nashville workforce, Oracle has signed a new 116,000 square foot lease within The Neuhoff District, at 1320 Adams Street. With this latest investment, Oracle will bring its office capacity in Nashville to about 2,000 seats across three locations, marking significant progress in the company's plans to create thousands of new tech jobs and become a cornerstone of the local economy. "New candidates as wel

    3/26/26 6:49:00 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Veritone Announces Strategic Agreement with Oracle to Accelerate Enterprise AI and AI Data Economy

    Multi-year partnership will support Veritone's global growth and AI expansion across commercial and public sectors, Veritone Data Refinery, and Veritone Data Marketplace Veritone, Inc. (NASDAQ:VERI), a leader in building enterprise AI and data solutions, today announced that it has signed a multi-year agreement with Oracle to migrate Veritone AI solutions to Oracle Cloud Infrastructure (OCI). By adopting OCI as a preferred cloud and infrastructure provider, Veritone will enhance the scalability, security, and performance of its AI offerings, including its aiWARE platform, Veritone Data Refinery (VDR) and Veritone Data Marketplace (VDM). As the demand for scalable, secure, and sovereign

    3/26/26 4:33:00 PM ET
    $ORCL
    $VERI
    Computer Software: Prepackaged Software
    Technology
    EDP Services

    Oracle Unveils AI Database Agentic Innovations for Business Data

    New agentic AI capabilities designed for business data accelerate enterprise innovation and help defend enterprises from AI-era threats Available on all platforms from multicloud to on-premisesLONDON, March 24, 2026 /PRNewswire/ -- Oracle AI World Tour -- Oracle today announced new agentic AI innovations for Oracle AI Database that will help customers rapidly build, deploy, and scale secure agentic AI applications that are suitable for full-scale production workloads. Oracle AI Database architects agentic AI and data together across operational databases and analytic lakehouses. It enables AI agents to securely access real-time enterprise data wherever it resides and easily use business data

    3/24/26 4:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $ORCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Magouyrk Clayton M. sold $1,552,318 worth of shares (10,000 units at $155.23), decreasing direct ownership by 7% to 134,030 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    2/11/26 4:42:45 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by EVP, Chief Legal Officer Levey Stuart

    4 - ORACLE CORP (0001341439) (Issuer)

    1/26/26 5:15:41 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    EVP, Principal Financial Offcr Kehring Douglas A sold $6,821,150 worth of shares (35,000 units at $194.89), decreasing direct ownership by 51% to 33,638 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    1/16/26 4:15:34 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $ORCL
    Leadership Updates

    Live Leadership Updates

    View All

    Oracle Scales Up Nashville Offices to Support Rapid Growth

    New lease at the Neuhoff Development adds over 116,000 square feet to Oracle's Nashville footprintAUSTIN, Texas, March 26, 2026 /PRNewswire/ -- To accommodate future growth of its Nashville workforce, Oracle has signed a new 116,000 square foot lease within The Neuhoff District, at 1320 Adams Street. With this latest investment, Oracle will bring its office capacity in Nashville to about 2,000 seats across three locations, marking significant progress in the company's plans to create thousands of new tech jobs and become a cornerstone of the local economy. "New candidates as wel

    3/26/26 6:49:00 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Health Systems Simplify Secure Data Exchange with Oracle Health

    New Oracle Health Connection Hub delivers single, unified console to enable data sharing control, auditing, and governance so health systems can easily manage a broad range of interoperability services Early adopters see 50 percent reduction in processing times of Social Security Administration disability benefit claims AUSTIN, Texas, Oct. 9, 2025 /PRNewswire/ -- Oracle Health Connection Hub is now generally available for U.S. healthcare providers, enabling them to use a single console to more easily onboard, access, and manage preferences for Oracle Health interoperability solutions. The latest step in Oracle's strategy to increase interoperability and reduce friction between payers and pr

    10/9/25 9:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SoftBank Group to Acquire Ampere Computing

    SoftBank Group Corp. (TSE: 9984, "SoftBank Group") today announced that it will acquire Ampere® Computing, a leading independent silicon design company, in an all-cash transaction valued at $6.5 billion. Under the terms of the agreement, Ampere will operate as a wholly owned subsidiary of SoftBank Group and retain its name. As part of the transaction, Ampere's lead investors – Carlyle (NASDAQ:CG) and Oracle Corp. (NYSE:ORCL) – are selling their respective positions in Ampere. As SoftBank Group broadens its AI infrastructure investments in ventures such as Cristal intelligence and Stargate, the acquisition will help enhance SoftBank Group's capabilities in key areas and accelerate its growt

    3/19/25 7:30:00 PM ET
    $CG
    $ORCL
    Investment Managers
    Finance
    Computer Software: Prepackaged Software
    Technology

    $ORCL
    Financials

    Live finance-specific insights

    View All

    Oracle Announces Fiscal Year 2026 Third Quarter Financial Results

    Q3 Remaining Performance Obligations $553 billion, up 325% year-over-year in USDQ3 GAAP Earnings per Share up 24% to $1.27, Non-GAAP Earnings per Share up 21% to $1.79Q3 Total Revenue $17.2 billion, up 22% in USD and up 18% in constant currencyQ3 Cloud Revenue (IaaS plus SaaS) $8.9 billion, up 44% in USD and up 41% in constant currency Q3 Cloud Infrastructure Revenue (IaaS) $4.9 billion, up 84% in USD and up 81% in constant currencyQ3 Oracle Cloud Database (IaaS) Revenue up 35%, Multicloud Database Revenue up 531% in USDQ3 Cloud Application (SaaS) Revenue $4.0 billion, up 13% in USD and up 11% in constant currencyQ3 Fusion Cloud ERP (SaaS) Revenue $1.1 billion, up 17% in USD and up 14% in co

    3/10/26 4:05:00 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Oracle Sets the Date for its Third Quarter Fiscal Year 2026 Earnings Announcement

    Earnings Results to be released on March 10, 2026, After the Close of the MarketAUSTIN, Texas, March 3, 2026 /PRNewswire/ -- Oracle Corporation today announced that its third quarter fiscal year 2026 results will be released on Tuesday, March 10th, after the close of the market. Oracle will host a conference call and live webcast at 4:00 p.m. Central Time to discuss the financial results.  The live webcast will be available on the Oracle Investor Relations website at www.oracle.com/investor. About OracleOracle offers integrated suites of applications plus secure, autonomous infr

    3/3/26 4:00:00 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Oracle Announces Fiscal Year 2026 Second Quarter Financial Results

    Q2 Remaining Performance Obligations $523 billion, up 438% in USDQ2 GAAP Earnings per Share up 91% to $2.10, Non-GAAP Earnings per Share up 54% to $2.26Q2 Total Revenue $16.1 billion, up 14% in USD and up 13% in constant currencyQ2 Cloud Revenue (IaaS plus SaaS) $8.0 billion, up 34% in USD and up 33% in constant currencyQ2 Cloud Infrastructure (IaaS) Revenue $4.1 billion, up 68% in USD and up 66% in constant currencyQ2 Cloud Application (SaaS) Revenue $3.9 billion, up 11% in both USD and constant currencyQ2 Fusion Cloud ERP (SaaS) Revenue $1.1 billion, up 18% in USD and up 17% in constant currencyQ2 NetSuite Cloud ERP (SaaS) Revenue $1.0 billion, up 13% in both USD and constant currencyAUSTI

    12/10/25 4:05:00 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $ORCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Oracle Corporation (Amendment)

    SC 13G/A - ORACLE CORP (0001341439) (Subject)

    2/9/24 4:33:37 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Oracle Corporation (Amendment)

    SC 13G/A - ORACLE CORP (0001341439) (Subject)

    2/10/23 4:31:02 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Oracle Corporation (Amendment)

    SC 13G/A - ORACLE CORP (0001341439) (Subject)

    2/10/22 8:28:11 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology